Last reviewed · How we verify

LTOT 24 h/day

Skane University Hospital · FDA-approved active Small molecule

LTOT 24 h/day delivers supplemental oxygen continuously throughout the day and night to maintain adequate blood oxygen levels in patients with chronic hypoxemia.

LTOT 24 h/day delivers supplemental oxygen continuously throughout the day and night to maintain adequate blood oxygen levels in patients with chronic hypoxemia. Used for Chronic obstructive pulmonary disease (COPD) with chronic hypoxemia, Interstitial lung disease with chronic hypoxemia, Other chronic respiratory conditions requiring continuous oxygen supplementation.

At a glance

Generic nameLTOT 24 h/day
Also known asLong-term oxygen therapy prescribed continuously (24 h/day)
SponsorSkane University Hospital
ModalitySmall molecule
Therapeutic areaRespiratory/Pulmonary
PhaseFDA-approved

Mechanism of action

Long-term oxygen therapy (LTOT) is a supportive treatment that increases inspired oxygen concentration to correct chronic hypoxemia (low blood oxygen). By delivering oxygen 24 hours daily, it reduces the work of breathing, decreases pulmonary vasoconstriction, and helps prevent secondary complications such as pulmonary hypertension and cor pulmonale in patients with chronic respiratory diseases.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: